Clinical Trials Browser

Terminated × Leiomyoma × telapristone acetate × Clear all

NCT02811159 2019-06-27

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Phase 2 Terminated

20 enrolled 16 charts

Leiomyoma

NCT00958893 2014-08-25

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Phase 2 Terminated

4 enrolled 1 chart

Leiomyoma

NCT00683917 2014-08-21

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Phase 2 Terminated

10 enrolled 1 chart

Leiomyoma

NCT00737282 2014-08-21

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Phase 3 Terminated

175 enrolled 1 chart

Leiomyoma

NCT00785356 2014-08-21

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

8 enrolled 1 chart

Classical hematology

Anemia, Leiomyoma

NCT00853567 2014-08-21

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

71 enrolled 1 chart

Leiomyoma

NCT01069120 2014-08-21

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

27 enrolled 1 chart

Leiomyoma